Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given
together with dexamethasone in treating patients with recurrent or refractory multiple
myeloma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving temsirolimus together with dexamethasone may kill more cancer cells.